NYSTATIN AND TRIAMCINOLONE ACETONIDE

N/A

Manufactured by Alembic Pharmaceuticals Inc.

237 FDA adverse event reports analyzed

Last updated: 2026-04-15

About NYSTATIN AND TRIAMCINOLONE ACETONIDE

NYSTATIN AND TRIAMCINOLONE ACETONIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Alembic Pharmaceuticals Inc.. The most commonly reported adverse reactions for NYSTATIN AND TRIAMCINOLONE ACETONIDE include DRUG INEFFECTIVE, PRODUCT USE IN UNAPPROVED INDICATION, APPLICATION SITE PAIN, PRURITUS, DRUG INEFFECTIVE FOR UNAPPROVED INDICATION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for NYSTATIN AND TRIAMCINOLONE ACETONIDE.

Top Adverse Reactions

DRUG INEFFECTIVE23 reports
PRODUCT USE IN UNAPPROVED INDICATION11 reports
APPLICATION SITE PAIN8 reports
PRURITUS8 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION6 reports
OFF LABEL USE5 reports
PAIN5 reports
RASH5 reports
ACCIDENTAL EXPOSURE TO PRODUCT4 reports
APPLICATION SITE PRURITUS4 reports
BURNING SENSATION4 reports
DRUG EFFECTIVE FOR UNAPPROVED INDICATION4 reports
FATIGUE4 reports
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION4 reports
NAUSEA4 reports
URINARY TRACT INFECTION4 reports
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS4 reports
APPLICATION SITE ERYTHEMA3 reports
CONDITION AGGRAVATED3 reports
DIARRHOEA3 reports
EXPIRED PRODUCT ADMINISTERED3 reports
HEADACHE3 reports
INCORRECT ROUTE OF PRODUCT ADMINISTRATION3 reports
PRODUCT CONTAINER ISSUE3 reports
PRODUCT QUALITY ISSUE3 reports
VOMITING3 reports
WEIGHT DECREASED3 reports
ABDOMINAL DISCOMFORT2 reports
APPLICATION SITE IRRITATION2 reports
BLOOD CHOLESTEROL INCREASED2 reports
CHEST PAIN2 reports
DEPRESSION2 reports
DIZZINESS2 reports
DRUG EFFECT DECREASED2 reports
DRY SKIN2 reports
DYSGEUSIA2 reports
ERYTHEMA2 reports
EYE IRRITATION2 reports
FUNGAL INFECTION2 reports
INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION2 reports
INCORRECT DRUG ADMINISTRATION DURATION2 reports
INSOMNIA2 reports
INTENTIONAL PRODUCT USE ISSUE2 reports
JOINT SWELLING2 reports
MALAISE2 reports
NO ADVERSE EVENT2 reports
PRODUCT DISPENSING ERROR2 reports
PRODUCT PHYSICAL CONSISTENCY ISSUE2 reports
RASH ERYTHEMATOUS2 reports
SKIN EXFOLIATION2 reports
SKIN IRRITATION2 reports
SWELLING FACE2 reports
THERAPEUTIC PRODUCT EFFECT INCOMPLETE2 reports
THERAPEUTIC RESPONSE UNEXPECTED2 reports
ABDOMINAL PAIN1 reports
ACTIVATED PARTIAL THROMBOPLASTIN TIME SHORTENED1 reports
ACTIVITIES OF DAILY LIVING IMPAIRED1 reports
ACUTE MYOCARDIAL INFARCTION1 reports
AFFECT LABILITY1 reports
AGITATION1 reports
ALANINE AMINOTRANSFERASE INCREASED1 reports
ALBUMIN GLOBULIN RATIO DECREASED1 reports
ALLERGIC REACTION TO EXCIPIENT1 reports
ANAEMIA1 reports
ANAPHYLACTIC REACTION1 reports
ANORECTAL DISCOMFORT1 reports
ANTISOCIAL BEHAVIOUR1 reports
APPLICATION SITE DISCOLOURATION1 reports
APPLICATION SITE HAEMORRHAGE1 reports
APPLICATION SITE RASH1 reports
APPLICATION SITE VESICLES1 reports
ASPARTATE AMINOTRANSFERASE INCREASED1 reports
ASTHENIA1 reports
ATRIAL FIBRILLATION1 reports
ATTENTION DEFICIT/HYPERACTIVITY DISORDER1 reports
AUTOIMMUNE HAEMOLYTIC ANAEMIA1 reports
AUTONOMIC NERVOUS SYSTEM IMBALANCE1 reports
BACK PAIN1 reports
BACTERIAL TEST POSITIVE1 reports
BACTERIAL VAGINOSIS1 reports
BLOOD ALBUMIN DECREASED1 reports
BLOOD BILIRUBIN INCREASED1 reports
BLOOD CHLORIDE INCREASED1 reports
BLOOD CREATININE DECREASED1 reports
BLOOD GLUCOSE INCREASED1 reports
BLOOD IRON INCREASED1 reports
BLOOD LACTATE DEHYDROGENASE INCREASED1 reports
BLOOD LACTIC ACID INCREASED1 reports
BLOOD POTASSIUM DECREASED1 reports
BLOOD UREA INCREASED1 reports
BLOOD URINE PRESENT1 reports
BORDERLINE GLAUCOMA1 reports
BREAST TENDERNESS1 reports
BRONCHIAL HYPERACTIVITY1 reports
C REACTIVE PROTEIN INCREASED1 reports
CARBON DIOXIDE DECREASED1 reports
CARDIAC FAILURE CONGESTIVE1 reports
CARDIO RESPIRATORY ARREST1 reports
CARDIOMYOPATHY1 reports
CEREBROVASCULAR ACCIDENT1 reports

Report Outcomes

Out of 102 classified reports for NYSTATIN AND TRIAMCINOLONE ACETONIDE:

Serious 8.8%Non-Serious 91.2%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female47 (73.4%)
Male17 (26.6%)

Reports by Age

Age 654 reports
Age 704 reports
Age 603 reports
Age 482 reports
Age 532 reports
Age 612 reports
Age 642 reports
Age 712 reports
Age 752 reports
Age 862 reports
Age 872 reports
Age 171 reports
Age 261 reports
Age 351 reports
Age 421 reports
Age 461 reports
Age 491 reports
Age 511 reports
Age 521 reports
Age 541 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with NYSTATIN AND TRIAMCINOLONE ACETONIDE?

This profile reflects 237 FDA FAERS reports that mention NYSTATIN AND TRIAMCINOLONE ACETONIDE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for NYSTATIN AND TRIAMCINOLONE ACETONIDE?

Frequently reported terms in FAERS include DRUG INEFFECTIVE, PRODUCT USE IN UNAPPROVED INDICATION, APPLICATION SITE PAIN, PRURITUS, DRUG INEFFECTIVE FOR UNAPPROVED INDICATION, OFF LABEL USE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures NYSTATIN AND TRIAMCINOLONE ACETONIDE?

Labeling and FAERS entries often list Alembic Pharmaceuticals Inc. in connection with NYSTATIN AND TRIAMCINOLONE ACETONIDE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.